Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9274113
APP PUB NO 20140220596A1
SERIAL NO

14249975

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDICINAL BIOCONVERGENCE RESEARCH CENTERSEOUL 151-1742 CROWN YUE QU SHI LIDONG HILL 56-1 SEOUL UNIVERSITY 105-1 HOLE 307 FLOOR

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kim, Sunghoon Seoul, KR 400 3449
Park, Min Chul Seoul, KR 30 135

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 1, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00